Inovio Pharmaceuticals, Inc. (INO) is a Biotechnology company in the Healthcare sector, currently trading at $1.11. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is INO = $6 (+440.5% upside).
Valuation: INO trades at a trailing Price-to-Earnings (P/E) of -6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.
Financials: revenue is $65,343, -78.6%/yr average growth. Net income is $85M (loss), growing at +31.5%/yr. Net profit margin is -130000% (negative). Gross margin is 100% (+53.6 pp trend).
Balance sheet: total debt is $9M against $24M equity (Debt-to-Equity (D/E) ratio 0.39, conservative). Current ratio is 1.4 (adequate). Debt-to-assets is 12.6%. Total assets: $74M.
Analyst outlook: 9 / 17 analysts rate INO as buy (53%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 50/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).
